GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT
With a growing body of knowledge on the promising advancements and recent clinical data of
 the third generations of the Greenlight PVP/XPS, it seems to be a real contender in the world
 of MIS. Contenders of Greenlight laser technology includes bipolar as well as Holmium laser
 technology.

 In this study the investigators planned to test the Greenlight (532-nm) laser PVP using (XPS)
 180W system compared to bipolar electro-vaporization, in reduction of LUTS secondary to small
 to moderate sized BPH in a prospective randomized trial.
Patients with LUTS due to BPH seen through the outpatient prostate clinic in the Mansoura UNC
 were assessed to evaluate if the patient is eligible to the study inclusion criteria.
 Patients who are meeting these criteria were asked to participate in this randomized
 comparative study and were provided with an informed consent form. Study participants were
 enrolled and randomized, and the appropriate scheduled procedures were performed.

 Preoperatively, all patients were thoroughly evaluated by medical history and physical exam,
 digital rectal exam (DRE), prostate specific antigen (PSA), urinalysis and urine culture,
 international index of prostate symptom score (IPSS), Quality of Life (QOL), transrectal
 ultrasound (TRUS) measurement of prostatic volume and biopsy whenever indicated, measurement
 of post-void residual assessment (PVR), and maximum urinary flow rate (Qmax). Preoperative
 flexible urethrocystoscopy was done when hematuria was the presenting symptom.
Inclusion Criteria:

 1. Patients' age ≥50 years

 2. LUTS secondary to BOO due to BPH who failed medical treatment

 3. International prostate symptom scores (IPSS) >15 and bother score (QOL) ≥ 3 (according
 to IPSS question 8)

 4. Peak urinary flow rate (Qmax) <15 ml/sec with at least 125 ml voided volume or
 Patients with acute urine retention secondary to BPH who failed trial of voiding on
 medical treatment.

 5. ASA (American society of anaesthesiologists) score ≤3.

 6. TRUS prostate size (from 30 to 80ml)

 Exclusion Criteria:

 1. Patient with neurological disorder which might affect bladder function as
 cerebrovascular stroke, Parkinson disease

 2. Active urinary tract infection,

 3. Presence of active bladder cancer (within the last 2 years)

 4. Known prostate cancer patients will be excluded preoperatively on the basis of digital
 rectal examination, prostate specific antigen level, and TRUS imaging followed by
 prostate biopsies if necessary.